

## PLENARY LECTURE

9.00 - 9.45  
AUDITORIUM

### BIOMARKER DETECTION, SPINNING BIOLOGICAL TRASH INTO DIAGNOSTIC GOLD

Chair: *M.A. Blankenstein (The Netherlands)*



**E.F. Petricoin III**

*Center for Applied Proteomics and  
Molecular Medicine  
George Mason University  
Manassas - USA*

Dr. **Emanuel F Petricoin** is the Co-Director of the *Center for Applied Proteomics and Molecular Medicine* (CAPMM) at George Mason University. Prior to this position, he served as Co-Director of the FDA-NCI Clinical Proteomics Program from 2001-2005, and a Senior Investigator within the Center for Biologics Evaluation and Research at the US Food and Drug Administration since 1996. He received his PhD in Microbiology from the University of Maryland in 1990 where he was the first to characterise and clone genes involved in lipopolysaccharide biosynthesis in *Neisseria gonorrhoeae*. As a post-doctoral fellow at the US Food and Drug Administration, he and his colleagues discovered and characterised the JAK-STAT signaling pathway. His expertise centers on translational research for applications of novel proteomics and nano- technologies for patient tailored medicine and clinical diagnostics. He is a co-inventor on 15 filed and published patents, and has authored over 170 peer-reviewed publications and invited reviews. He was a co-author on several important FDA Guidance Documents and Points-to-Consider documents including the Pharmacogenomics Guidance Documents. He has authored over 40 book chapters, is on the editorial board of *Proteomics*, *Journal of Proteome Research*, *Biomedical Microdevices*, *Molecular Carcinogenesis*, and served as a Senior Editor for *Cancer Epidemiology Biomarkers and Prevention*. He was the founding Co-Editor-in-Chief of *Clinical Proteomics*. Dr. Petricoin is a founding member of the *Human Proteomic Organization* (HUPO) as well as the US HUPO, and served on the Executive Committee and Treasurer for HUPO from 2002-2004. While at the FDA, he served on the FDA's Pharmacogenomics Advisory Board, and the Nanotechnology Advisory Board. He has received numerous awards including the NIH Director's Award, FDA Distinguished Scientist Award, American Society of Cytopathology Basic Research Award, the Roche Diagnostics/CLAS Distinguished Scientist Award and the Harvard University Leading Edge Award.

Wednesday 6 June 9.00 - 9.45

41

## 10.00 - 12.30 AUDITORIUM

### BLEEDING DISORDERS

---

Chairs: L. Muszbek (Hungary)  
A. Sturk (The Netherlands)



**10.00 - 10.30**  
Diagnosis and treatment of venous thromboembolism  
*S. Middeldorp (The Netherlands)*

**10.30 - 11.00**  
Qualitative platelet disorders  
*A.T. Nurden (France)*

**11.00 - 11.30**  
Pathophysiology of the antiphospholipid syndrome  
*P.G. de Groot (The Netherlands)*

**11.30 - 12.00**  
Diagnosis of inherited and acquired factor XIII deficiencies  
*L. Muszbek (Hungary)*

---

### **Free communications:**

**12.00 - 12.15**  
Gender and menstrual cycle influence circulating microparticles  
*B. Toth (The Netherlands)*

**12.15 - 12.30**  
Inhibition of microparticle release triggers endothelial apoptosis and detachment  
*A. Sturk (The Netherlands)*

### SOCIAL EVENTS

**18.45**  
*Congress Party and NVKC 60<sup>th</sup> Anniversary at the Beurs van Berlage.*

*For further information on social events see pages 169-170*

**10.00 - 12.30**  
**FORUM**

**METABOLIC DISEASE**

---

Chairs: F. Salvatore (Italy)  
F. van den Bergh  
(The Netherlands)

**10.00 - 10.30**

The pathology of oxidative phosphorylation disorders  
*L.G. Nijtmans (The Netherlands)*

**10.30 - 11.00**

Laboratory diagnosis of lysosomal storage diseases  
*I. Maire (France)*

**11.00 - 11.30**

Holo-transcobalamin, measurement and clinical utility  
*E. Nexø (Denmark)*

**11.30 - 12.00**

Hereditary fructose intolerance: from clinics to protein  
*F. Salvatore (Italy)*

---

***Free communications:***

**12.00 - 12.15**

Are cerebral creatine deficiency syndromes included in the differential diagnosis of mental retardation of unknown cause?  
*G.S. Salomons (The Netherlands)*

**12.15 - 12.30**

Extended neonatal screening and the importance of enzymatic studies in lymphocytis in order to discriminate between false- and true-positives  
*R.J.A. Wanders (The Netherlands)*

**10.00 - 12.30**  
**ROOM N/O**

**DRUGS OF ABUSE,  
THERAPEUTIC DRUG  
MONITORING**

---

Chairs: M. Oellerich (Germany)  
G. van der Sluijs Veer  
(The Netherlands)

**10.00 - 10.30**

Detection of drugs of abuse in athletes  
*D. de Boer (The Netherlands)*

**10.30 - 11.00**

Biomarkers: the link between therapeutic drug monitoring and pharmacodynamics  
*M. Oellerich (Germany)*

**11.00 - 11.30**

The use of metabolic ratios of psychotropic drugs as indication of genotype: clinical applications  
*J. van der Weide (The Netherlands)*

**11.30 - 12.00**

Drug testing in the criminal justice system  
*A.D. Fraser (Canada)*

10.00 - 12.30

43 Wednesday 6 June

**10.00 - 12.30**  
**ROOM A**

## SCIENTIFIC COMMUNICATIONS



Chairs: A. Wootton (Australia)  
M.T.M. Raijmakers  
(The Netherlands)

**10.00 - 10.30**

Recording and distributing audio lectures  
*C. Webster (UK)*

**10.30 - 11.00**

Creating interactive educational material  
*A.M. Wootton (Australia)*

**11.00 - 11.30**

Website conception and information design  
*G. Sypniewska (Poland)*

**11.30 - 12.00**

Improving your presentations and posters  
*J.B. Lopez (Malaysia)*



## POSTERS

*Poster display:* **10.00 - 17.30**

Allergy	W001-W007
Autoimmune diseases	W008-W027
Blood banking and Haemovigilance	W028-W030
Cancer/Tumor markers	W031-W118
Cardiovascular disease:	
Heart failure/Hypertension	W119-W166
Clinical relevance of Laboratory Testing	W167-W209
Critical care	W210-W223
Immunology/	And W366
Antibody technology	W225-W249
	And W367
Inherited and acquired metabolic disease	W250-W263
Lipids and lipoproteins	W264-W298
Molecular diagnostics	W299-W325
Paediatric clinical chemistry	W326-W343
Proteins and proteomics/	
Chips and Mass Spectrometry	W344-W355
Traceability and	
Standardization	W356-W365
	And W368

Authors are asked to present their poster **from 13:30 until 14:30** in order to encourage scientific discussion.

See **page 166** for further information on posters. See **pages 108-125** for the list of posters displayed on Wednesday 6 June and **pages 127-161** for the authors' index.

15.00 - 17.30  
AUDITORIUM

## CONTRIBUTION OF LABORATORY MEDICINE IN KIDNEY DISEASE

ifcc symposium

Chairs: M. Thomas (UK)  
F. Hoek (The Netherlands)

15.00 - 15.30

Estimating Kidney function using creatinine based equations: impact on conventional creatinine reference ranges when establishing traceability to the isotope dilution gc mass spectrometry (idms) reference method

*N. Greenberg (USA)*

15.30 - 16.00

Cystatin C as estimator of glomerular filtration rate: needs for its definitive implementation

*A. Grubb (Sweden)*

16.00 - 16.30

Measurement of urinary albumin: analytical aspects influencing its clinical use

*H.A. Morris (Australia)*

16.30 - 17.00

The importance of cardiac biomarkers in end-stage renal disease

*F.S. Apple (USA)*

***Free communications:***

17.00 - 17.15

Predictive value of both BNP and NT-proBNP is enhanced by CRP level in an hemodialysis population. *A.S. Bargnoux (France)*

17.15 - 17.30

Trueness verification of the current creatinine assays demonstrates a disappointing variability which insufficiently meets changing clinical needs. *J. Delanghe (Belgium)*

Kindly offered by

**DiaSys**

15.00 - 17.30  
FORUM

## CLINICAL CASES IN HAEMATOLOGY AND IMMUNOLOGY

Chairs: *R. van Oers (The Netherlands)*  
*H. Hooijkaas (The Netherlands)*

INTERACTIVE

A voting system will be provided at the entrance of the Forum room.

This session will allow delegates to interact with the speaker and make the session an active one!

15.00 - 17.30  
ROOM N/O

## OSTEOPOROSIS AND CALCIUM HOMEOSTASIS

---

Chairs: W.D. Fraser (UK)  
J.P.M. Wielders  
(The Netherlands)

15.00 - 15.30

Vitamin D assays revisited  
*W.D. Fraser (UK)*

15.30 - 16.00

Vitamin D signalling in health and  
disease  
*F. Jakob (Germany)*

16.00 - 16.30

Vitamin D in the Elderly: A Hormone  
in Disguise  
*G. Duque (Canada)*

16.30 - 17.00

Bone markers and osteoporosis  
*A. Griesmacher (Austria)*

---

### **Free communications:**

17.00 - 17.15

Vitamin D deficiency in newborns of mothers  
in a multicultural society  
*J.W. Janssen (The Netherlands)*

17.15 - 17.30

Estrogen-related receptor gamma genotype  
influences bone mass in a healthy population  
of french-canadian women  
*F. Rousseau (Canada)*

15.00 - 17.30  
ROOM A

## YOUR FUTURE IN PATIENT CARE - II: LABORATORY RESPONSE TO CHANGING REGULATORY ENVIRONMENT

---

Chairs: S. Zérah (France)  
W. Huisman (The Netherlands)

15.00 - 15.30

Biobanking in relation to clinical  
information  
*J.E. Litton (Sweden)*

15.30 - 16.00

Contribution of the laboratory to  
patient safety  
*J.D.S. Kay (UK)*

16.00 - 16.30

EC4 - Clinical laboratory globalisation:  
The EU directives  
*R.T.P. Jansen (The Netherlands)*

16.30 - 17.00

EC4: Recent developments on  
accreditation and validation  
*W. Huisman (The Netherlands)*

---

### **Free communications:**

17.00 - 17.15

Reflective testing - what do general  
practitioners in the Netherlands think?  
*W.P. Oosterhuis (The Netherlands)*

17.15 - 17.30

Medial: a cost-effective back office laboratory  
concept integrated within the primary  
medical care process  
*J.P.M.C. Gorgels (The Netherlands)*

## MEETINGS DURING THE CONGRESS

### ART ROOM

#### ■ 10.00 - 13.00 CLOSED MEETING

*Bergmeyer Conference Steering Committee*

Chair: M. Panteghini (Italy)

### BOARD FORUM

#### ■ 15.30 - 17.30 CLOSED MEETING

*Molecular Diagnostics Meeting (C-MD)*

Chair: F. Rousseau (Canada)

### PRESS FORUM

#### ■ 9.00 - 13.00 CLOSED MEETING

*Meeting of the IFCC Committee on Reference Intervals and Decision Limits (C-RIDL)*

Chair: F. Ceriotti (Italy)

#### ■ 13.30 - 17.30

*EC4 Project Group Cardiac Markers*

Chair: P. Laitinen (Finland)

### ROOM C

#### ■ 13.30 - 16.30 CLOSED MEETING

*Working group "Growth hormone"*

Chair: M. Bidlingmaier (Germany)

### ROOM D

#### ■ 13.30 - 15.00 - OPEN MEETING

*Towards a European Network on Clinical Pharmacogenetics.*

Chairs: RHN van Schaik (The Netherlands)  
M. Oellerich (Germany)

See programme on page 48

### ROOM E+F

#### ■ 14.00 - 16.00 OPEN MEETING

Chairs: B.G.Blijenberg  
(The Netherlands)  
J.J. Heeren (The Netherlands)

*NVVC Symposium on the history of clinical chemistry*

See programme on page 48

See also page 174



MEETINGS -  
Wednesday 5 June

## OPEN MEETINGS DURING THE CONGRESS

### ROOM D - 13.30-15.00

#### Towards a European Network on Clinical Pharmacogenetics

Chairs: R.H.N. van Schaik (The Netherlands )  
M. Oellerich (Germany)

13.30

#### Why a European Network on Clinical Pharmacogenetics (EU-PGX)?

*R.H.N. van Schaik (The Netherlands)*

13.50

#### Translation of pharmacogenetics into clinical practice: development of NACB guidelines for pharmacogenetic testing. An update.

*D. Payne (USA)*

14.10

#### Proficiency testing for pharmacogenetics in Germany.

*M. Neumaier (Germany)*

14.30

#### General discussion

14.50

#### Closing remarks

*R.H.N. van Schaik (The Netherlands)*

### ROOM E+F - 14.00-16.00

#### NVKC Symposium on the history of clinical chemistry

Chairs: B.G.Blijenberg (The Netherlands)  
J.J. Heeren (The Netherlands)

14.00

#### Opening by Dr. J.W. Janssen - *President NVKC*

14.10

#### A iatrochemist's view on health and disease

*H. Beukers (The Netherlands)*

14.40

#### The exponential growth of clinical chemistry; our Inheritance (with some attention to Dutch Contributions)

*J.G. Lines (UK)*

15.10

#### A Century of Hormones: from conductors to players in an orchestra

*J.H.H. Thijssen (The Netherlands)*

15.40

#### Discussion

*See page 174 for the Historical Exhibition.*



Wednesday 6 June

-MEETINGS-

48